Sign in Subscribe
Hematology

Imatinib Mesylate (STI571) Demonstrates Promising Results in Treating Multiple Myeloma

Strategic Insights

— 1 min read

Researchers at the University of Coimbra in Spain have made a significant breakthrough in the treatment of multiple myeloma, a type of blood cancer, by discovering that Imatinib Mesylate (STI571) can suppress the proliferation of tumor cells in vitro. According to a recent study published in the British Journal of Haematology, STI571 effectively inhibits the growth of multiple myeloma cells, even in those that are resistant to common treatments such as dexamethasone and melphalan. The study's findings suggest that STI571 may be a valuable addition to existing therapies for multiple myeloma.

Key Takeaways:

  • The researchers used STI571, an inhibitor of c-Kit, to investigate its effect on multiple myeloma cells.
  • STI571 inhibited the proliferation of MM cells by arresting cell cycle progression, as shown by Western blotting of cell cycle proteins.
  • The levels of p21 and p16, proteins involved in cell cycle regulation, were increased by STI571 treatment.
  • STI571 was effective in inhibiting MM cells that were resistant to dexamethasone or melphalan.
  • The study suggests that STI571 may act on targets other than c-Kit, as its effect was observed in MM cells that did not express the receptor protein.
  • Combining STI571 with dexamethasone resulted in an additive effect, making it a promising combination therapy for multiple myeloma.
  • The authors concluded that understanding the action of STI571 in MM cells may reveal new targets for the treatment of multiple myeloma and other disorders.

Statistics:

  • 5: The number of patients with multiple myeloma that were studied.
  • 3: The number of cell lines that were used for the study.
  • 2: The number of cell cycle proteins whose levels were increased by STI571 treatment (p21 and p16).
  • 1: The year in which the study was published.
  • 2003: The publication date of the study.

Sources:

  • Pandiella, A., et al. (2003). Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol, 123(5), 858-868.
  • University of Coimbra, Center for Cancer Investigation, Institute of Microbiological Biochemistry, Avenida, Campus Miguel Unamuno, Salamanca, Spain.
  • Blackwell Publishing Ltd., 9600 Garsington Rd., Oxford OX4 2DG, UK.

Read more